Our Metabolomics study on Chronic Fatigue Syndrome was published August 2016 in the Proceedings of the National Academay of Sciences (PNAS), one of the most prestigious medical journals in the US and the world. This ground breaking study is changing the way chronic illness, and Chronic Fatigue Syndrome in particular will be understood and treated.
Chronic fatigue syndrome is a multisystem disease that causes long-term pain and disability. It is difficult to diagnose because of its protean symptoms and the lack of a diagnostic laboratory test. We report that targeted, broad-spectrum metabolomics of plasma not only revealed a characteristic chemical signature but also revealed an unexpected underlying biology. Metabolomics showed that chronic fatigue syndrome is a highly concerted hypometabolic response to environmental stress that traces to mitochondria and was similar to the classically studied developmental state of dauer. This discovery opens a fresh path for the rational development of new therapeutics and identifies metabolomics as a powerful tool to identify the chemical differences that contribute to health and disease.